ID   CPT-K5
AC   CVCL_2878
SY   CPT-K-5; CPTK5; RPMI 8402/CPTK5
DR   BioSample; SAMN03472497
DR   cancercelllines; CVCL_2878
DR   JCRB; JCRB1067
DR   Wikidata; Q54814409
RX   PubMed=1849260;
RX   PubMed=3039492;
RX   PubMed=14679002;
RX   PubMed=29496689;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; CPT-11).
CC   Sequence variation: Gene fusion; HGNC; 10879; STIL + HGNC; 11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (PubMed=29496689).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu1583_Gln1584insProValGluLeuMetProProGlu (c.4750_4751insCCGTGGAGCTGATGCCGCCGGAGC); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg159Ser (c.477G>T); ClinVar=VCV000375959; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Asp533Gly (c.1598A>G); ClinVar=VCV000016773; Zygosity=Unspecified (PubMed=1849260).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Ser121Ter (c.362C>A); Zygosity=Heterozygous (from parent cell line).
CC   Omics: Array-based CGH.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): JCRB; PubMed=29496689
ST   Amelogenin: X
ST   CSF1PO: 9,10,11,12
ST   D13S317: 10,12
ST   D16S539: 10,14
ST   D18S51: 14,17,18
ST   D19S433: 14,15
ST   D21S11: 28,30,33.2,34.2
ST   D2S1338: 23,24,26,27
ST   D3S1358: 14,15,16
ST   D5S818: 11,12,13
ST   D7S820: 9,12,14
ST   D8S1179: 13,14
ST   FGA: 21,22,24
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 17,18,20,22
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1667 ! RPMI-8402
SX   Female
AG   16Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   PubMed=1849260; DOI=10.1093/nar/19.1.69;
RA   Tamura H.-o., Kohchi C., Yamada R., Ikeda T., Koiwai O., Patterson E.,
RA   Keene J.D., Okada K., Kjeldsen E., Nishikawa K., Andoh T.;
RT   "Molecular cloning of a cDNA of a camptothecin-resistant human DNA
RT   topoisomerase I and identification of mutation sites.";
RL   Nucleic Acids Res. 19:69-75(1991).
//
RX   PubMed=3039492; DOI=10.1073/pnas.84.16.5565;
RA   Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y.,
RA   Okada K.;
RT   "Characterization of a mammalian mutant with a camptothecin-resistant
RT   DNA topoisomerase I.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:5565-5569(1987).
//
RX   PubMed=14679002;
RA   Li T.-K., Houghton P.J., Desai S.D., Daroui P., Liu A.A., Hars E.S.,
RA   Ruchelman A.L., LaVoie E.J., Liu L.F.;
RT   "Characterization of ARC-111 as a novel topoisomerase I-targeting
RT   anticancer drug.";
RL   Cancer Res. 63:8400-8407(2003).
//
RX   PubMed=29496689; DOI=10.21873/cgp.20068;
RA   Kjeldsen E., Nielsen C.J.F., Roy A., Tesauro C., Jakobsen A.-K.,
RA   Stougaard M., Knudsen B.R.;
RT   "Characterization of camptothecin-induced genomic changes in the
RT   camptothecin-resistant T-ALL-derived cell line CPT-K5.";
RL   Cancer Genomics Proteomics 15:91-114(2018).
//